[Calcium and calcium-channel blockers in the healing of an experimental myocardial infarct]. 1992

V N Sokrut, and N I Iabluchanskiĭ, and L A Pavlenko

It has been shown in experiments on 36 dogs with experimental myocardial infarction (MI) that the effect of calcium and blockers of calcium channels largely depends on the initial condition of reactivity and is realized via changes in lipid peroxidation (LPO). In MI, calcium enhances necrotic processes whereby aggravating disorders in its healing in case of high reactivity and returns them to normal, thus contributing to optimization of its healing in animals with low reactivity. Calcium channels blockers attenuate necrotic processes associated with MI and lead to its better healing in the presence of high reactivity and aggravate disorders in its healing in animals with low reactivity. Consideration of the body reactivity, the differentiated use of calcium drugs and calcium channels blockers should be regarded as an effective approach to optimization of the healing of complicated forms of MI.

UI MeSH Term Description Entries
D008070 Lipopolysaccharides Lipid-containing polysaccharides which are endotoxins and important group-specific antigens. They are often derived from the cell wall of gram-negative bacteria and induce immunoglobulin secretion. The lipopolysaccharide molecule consists of three parts: LIPID A, core polysaccharide, and O-specific chains (O ANTIGENS). When derived from Escherichia coli, lipopolysaccharides serve as polyclonal B-cell mitogens commonly used in laboratory immunology. (From Dorland, 28th ed) Lipopolysaccharide,Lipoglycans
D009203 Myocardial Infarction NECROSIS of the MYOCARDIUM caused by an obstruction of the blood supply to the heart (CORONARY CIRCULATION). Cardiovascular Stroke,Heart Attack,Myocardial Infarct,Cardiovascular Strokes,Heart Attacks,Infarct, Myocardial,Infarction, Myocardial,Infarctions, Myocardial,Infarcts, Myocardial,Myocardial Infarctions,Myocardial Infarcts,Stroke, Cardiovascular,Strokes, Cardiovascular
D009206 Myocardium The muscle tissue of the HEART. It is composed of striated, involuntary muscle cells (MYOCYTES, CARDIAC) connected to form the contractile pump to generate blood flow. Muscle, Cardiac,Muscle, Heart,Cardiac Muscle,Myocardia,Cardiac Muscles,Heart Muscle,Heart Muscles,Muscles, Cardiac,Muscles, Heart
D009336 Necrosis The death of cells in an organ or tissue due to disease, injury or failure of the blood supply.
D011749 Pyrogens Substances capable of increasing BODY TEMPERATURE and cause FEVER and may be used for FEVER THERAPY. They may be of microbial origin, often POLYSACCHARIDES, and may contaminate distilled water. Pyrogen
D002118 Calcium A basic element found in nearly all tissues. It is a member of the alkaline earth family of metals with the atomic symbol Ca, atomic number 20, and atomic weight 40. Calcium is the most abundant mineral in the body and combines with phosphorus to form calcium phosphate in the bones and teeth. It is essential for the normal functioning of nerves and muscles and plays a role in blood coagulation (as factor IV) and in many enzymatic processes. Coagulation Factor IV,Factor IV,Blood Coagulation Factor IV,Calcium-40,Calcium 40,Factor IV, Coagulation
D002121 Calcium Channel Blockers A class of drugs that act by selective inhibition of calcium influx through cellular membranes. Calcium Antagonists, Exogenous,Calcium Blockaders, Exogenous,Calcium Channel Antagonist,Calcium Channel Blocker,Calcium Channel Blocking Drug,Calcium Inhibitors, Exogenous,Channel Blockers, Calcium,Exogenous Calcium Blockader,Exogenous Calcium Inhibitor,Calcium Channel Antagonists,Calcium Channel Blocking Drugs,Exogenous Calcium Antagonists,Exogenous Calcium Blockaders,Exogenous Calcium Inhibitors,Antagonist, Calcium Channel,Antagonists, Calcium Channel,Antagonists, Exogenous Calcium,Blockader, Exogenous Calcium,Blocker, Calcium Channel,Blockers, Calcium Channel,Calcium Blockader, Exogenous,Calcium Inhibitor, Exogenous,Channel Antagonist, Calcium,Channel Blocker, Calcium,Inhibitor, Exogenous Calcium
D004195 Disease Models, Animal Naturally-occurring or experimentally-induced animal diseases with pathological processes analogous to human diseases. Animal Disease Model,Animal Disease Models,Disease Model, Animal
D004285 Dogs The domestic dog, Canis familiaris, comprising about 400 breeds, of the carnivore family CANIDAE. They are worldwide in distribution and live in association with people. (Walker's Mammals of the World, 5th ed, p1065) Canis familiaris,Dog
D004353 Drug Evaluation, Preclinical Preclinical testing of drugs in experimental animals or in vitro for their biological and toxic effects and potential clinical applications. Drug Screening,Evaluation Studies, Drug, Pre-Clinical,Drug Evaluation Studies, Preclinical,Drug Evaluations, Preclinical,Evaluation Studies, Drug, Preclinical,Evaluation, Preclinical Drug,Evaluations, Preclinical Drug,Medicinal Plants Testing, Preclinical,Preclinical Drug Evaluation,Preclinical Drug Evaluations,Drug Screenings,Screening, Drug,Screenings, Drug

Related Publications

V N Sokrut, and N I Iabluchanskiĭ, and L A Pavlenko
June 1993, Ceskoslovenska farmacie,
V N Sokrut, and N I Iabluchanskiĭ, and L A Pavlenko
September 1991, Journal of the American College of Cardiology,
V N Sokrut, and N I Iabluchanskiĭ, and L A Pavlenko
April 1986, Indian journal of experimental biology,
V N Sokrut, and N I Iabluchanskiĭ, and L A Pavlenko
January 1996, The Journal of family practice,
V N Sokrut, and N I Iabluchanskiĭ, and L A Pavlenko
July 1989, Archives of internal medicine,
V N Sokrut, and N I Iabluchanskiĭ, and L A Pavlenko
January 1990, BMJ (Clinical research ed.),
V N Sokrut, and N I Iabluchanskiĭ, and L A Pavlenko
December 2018, Iranian journal of basic medical sciences,
V N Sokrut, and N I Iabluchanskiĭ, and L A Pavlenko
January 1985, The American journal of cardiology,
V N Sokrut, and N I Iabluchanskiĭ, and L A Pavlenko
June 2023, JACC. Asia,
V N Sokrut, and N I Iabluchanskiĭ, and L A Pavlenko
January 1989, DICP : the annals of pharmacotherapy,
Copied contents to your clipboard!